In essence, the principal findings of this investigation may be encapsulated as follows: firstly, there was no discernible discrepancy in the incidence of all-cause mortality, cerebrovascular mortality, or stroke between the two groups of subjects (those treated with P2Y12 inhibitors and those treated with aspirin). This evidence concerns the gene P2RY12 and Stroke.